Resource Logo
BETA

BETA 2010 Summer/Fall; 22(4)

BETA 2010 Summer/Fall; 22(4)






 

In Memoriam: Randy Allgaier

This issue of BETA is dedicated to the memory of Randy Allgaier, a local and national hero in the fight against AIDS, who passed away on November 27. Randy was a former SFAF staff member, a warm and collegial community advocate, and a true champion for people living with HIV and AIDS in San Francisco and beyond. This issue of BETA includes an article on aging with HIV and a feature story on HIV and cancer—topics central to Randy’s recent passions and personal experience. We will miss him sorely.

For more information or a free subscription: (415) 487-8060 beta@sfaf.org

Sex Work, Criminalization, and HIV: Lessons from Advocacy History

Sex workers are frequently omitted from discussions about the links between criminalization, marginaliza­tion, and increased HIV transmission. We talk a lot about the effects of this dynamic on men who have sex with men, injection drug users, and peo­ple living with HIV—as we certainly should—but not about sex workers. Why is this group not like the others?

Read more...

A Glass Half Full: Cancer Risk for People Living with HIV

Cancer cannot be mentioned without arousing anxiety. But there is reason to believe the glass is at least half full when it comes to people with HIV and their risk for cancer.

Read more...

The iPrEx Results: Lifting Hopes, Raising Questions

Thanksgiving week was a truly auspicious time for results to be released from the first clinical trial evaluating the use of antiretroviral treatment to prevent HIV infection among gay men and transgenders. There was much to be thankful for: Data from the iPrEx study showed that taking once-daily tenofovir/emtricitabine (Truvada), as part of a comprehensive HIV prevention package, reduced new infections by about 44%.

Read more...

News Briefs

The XVIII International AIDS Conference (AIDS 2010), a large biannual meeting encompassing all aspects of the HIV pandemic, took place July 18-23 in Vienna, Austria. Selected reports from this conference and others are included, along with recent news from medical journals and other sources.

Read more...

Drug Watch: Tesamorelin Update

Since it first became available in the mid-1990s, highly active antiretroviral therapy (HAART) has saved lives and improved health and quality of life for countless people living with HIV—but the drugs are not without their downsides. One of these became clear within a few years after HAART was introduced, when people taking the new drugs began to experience dramatic and disturbing body shape changes caused by shifts in where fat accumulates.

Read more...

Aging and HIV: Emerging Issues in Research, Treatment, and Care

Thanks to better HIV treatments—and the efforts of treatment advocates—people are living longer with HIV. As HIV positive people get older, and as increasing numbers of people acquire HIV at an older age, the medical, emotional, and social issues typically associated with aging are compounded by HIV-related challenges.

Read more...

Open Clinical Trials

A selection of currently enrolling clini­cal trials of antiretroviral therapy (ART), and therapies for HIV/AIDS-related conditions.

Read more...

HAART Chart - Approved Antiretroviral Drugs



 


Copyright © 2010 -BETA, Publisher. All rights reserved to the San Francisco AIDS Foundation. Reproduced by permission. Reproduction of this article (other than one copy for personal reference) must be cleared through BETA: PO Box 426182, San Francisco, CA 94142-6182. Tel: 415 487 8060 Fax: 415 487 8069 San Francisco AIDS Foundation, Mail SFAF..

Information in this article was accurate in September 10, 2010. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.